Compare IMCR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | TYRA |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2016 | 2021 |
| Metric | IMCR | TYRA |
|---|---|---|
| Price | $26.33 | $20.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $59.30 | $47.45 |
| AVG Volume (30 Days) | 414.0K | ★ 530.2K |
| Earning Date | 11-06-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $9.28 | N/A |
| Revenue Next Year | $9.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $26.53 | $18.25 |
| 52 Week High | $40.71 | $40.65 |
| Indicator | IMCR | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 43.93 |
| Support Level | N/A | $18.46 |
| Resistance Level | $31.75 | $22.69 |
| Average True Range (ATR) | 1.46 | 1.15 |
| MACD | -0.46 | -0.08 |
| Stochastic Oscillator | 9.12 | 19.25 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.